Literature DB >> 23145941

Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals.

Dalziza Victalina Almeida1, Mariza Gonçalvez Morgado, Fernanda Heloise Côrtes, Monick Lindermeyer Guimarães, Leila Mendonça-Lima, Jose Henrique Pilotto, Beatriz Grinsztejn, Valdiléa Gonçalves Veloso, Vera Bongertz.   

Abstract

Tests for the detection of the humoral immune response to HIV-1 have to be standardized and established, demanding regional efforts. For this purpose the neutralizing antibody (NAb) assay for HIV-1 in TZM-bl cells was introduced in Brazil. Twenty plasma samples from HIV-1-infected individuals were assayed: 10 progressors and 10 long-term nonprogressors. These were tested against eight env-pseudotyped viruses (psVs) in the TZM-bl NAb assay and against HIV-1 strain HTLV/IIIB (HIV-1 IIIB) in primary lymphocytes. Forty-four percent of the samples showed neutralizing titers for psVs and 55% for HIV-1 IIIB. Plasma from progressors showed a broader neutralization and a higher potency. The introduction of these reference reagents encourages the participation of Brazil in future comparative assessments of anti-HIV-1 antibodies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23145941      PMCID： PMC3582229          DOI： 10.1089/AID.2012.0052

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  28 in total

1.  V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F.

Authors:  M G Morgado; E C Sabino; E G Shpaer; V Bongertz; L Brigido; M D Guimaraes; E A Castilho; B Galvão-Castro; J I Mullins; R M Hendry
Journal:  AIDS Res Hum Retroviruses       Date:  1994-05       Impact factor: 2.205

2.  Antibody to lymphadenopathy-associated virus in AIDS.

Authors:  D D Ho; T R Rota; M S Hirsch
Journal:  N Engl J Med       Date:  1985-03-07       Impact factor: 91.245

3.  Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals.

Authors:  V Bongertz; S L M Teixeira; B Grinztejn; J H Pilotto; V G Veloso; M G Morgado; F I Bastos; E P Ouverney
Journal:  Mem Inst Oswaldo Cruz       Date:  2005-04-12       Impact factor: 2.743

4.  Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity.

Authors:  V Bongertz; C I Costa; V G Veloso; B Grinsztejn; E C João Filho; G Calvet; J H Pilotto; M L Guimarães; M G Morgado
Journal:  Scand J Immunol       Date:  2001-03       Impact factor: 3.487

5.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

7.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection.

Authors:  P Carotenuto; D Looij; L Keldermans; F de Wolf; J Goudsmit
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

9.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226
View more
  2 in total

1.  Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.

Authors:  Narayanaiah Cheedarla; Babu Hemalatha; Brahmaiah Anangi; Kannan Muthuramalingam; Murugesan Selvachithiram; Pattabiraman Sathyamurthi; Nandagopal Kailasam; Raghavan Varadarajan; Soumya Swaminathan; Srikanth Prasad Tripathy; S Kalyanaraman Vaniambadi; D Ramanathan Vadakkupattu; Luke Elizabeth Hanna
Journal:  Front Immunol       Date:  2018-03-27       Impact factor: 7.561

2.  Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene.

Authors:  Dalziza Victalina de Almeida; Karine Venegas Macieira; Beatriz Gilda Jegerhorn Grinsztejn; Valdiléa Gonçalves Veloso Dos Santos; Monick Lindenmeyer Guimarães
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.